Competency Directory – Medical Affairs Professional Society

Medical Affairs: Future Custodians of Digital Health?

August 10, 2019

Organizations should take a strategic approach to digital health solutions and also treat them with the same level of rigor applied to traditional therapies. Within the industry, the consensus is that it is a case of when, not if, digital health solutions become the norm.

How to Reframe Strategy and Compete on Outcomes

July 31, 2019

In “How to Reframe Strategy and Compete on Outcomes,” John Singer, Global Head of Health Industry Strategy, Innovation and Technology at Wipro, elaborates on why Medical Affairs need to drive “big design” thinking to create value in the new outcomes-based healthcare world.

Self-Awareness: How to deepen your insight and see the blind spots that could be holding you back

May 20, 2019

Here we decode self-awareness – the best approach to self-analysis to avoid being trapped looking in the rear-view mirror – and how to find and fix your blindspots.

The Rise and Rise of Medical

April 30, 2019

In My Journey: The Rise & Rise of Medical, Dr. Ameet Nathwani discusses the need to define and measure our contribution, and why we need to join together as a community to shape the future of healthcare.

Digital Health: The Road Ahead for Medical Affairs

April 20, 2019

In “Digital Health: The Road Ahead for Medical Affairs,” CMO and Head of Medical Affairs & Pharmacovigilance at Bayer, Mike Devoy discusses Medical Affairs’ unique understanding of how value can be created and delivered, and the key role it plays in developing the evidence and solutions around that value in collaboration with internal and external partners.

Clinical Statistics for Non-Statisticians (Part 2 of 2)

March 27, 2019

Part 2 of this series will discuss statistical analysis in clinical trials including null/alternative hypotheses; statistical assumptions (type I error, significance level, type II error, statistical power); hypothesis testing; Statistics used in RCTs, including type of outcome measures, analysis of time-to-event variables (plotting and interpretation of Kaplan-Meier curves).

A Global Perspective on Conducting Early Access Programs

March 27, 2019

Early Access includes a variety of programs by which pharmaceutical companies make investigational therapies available to patients with life-threatening diseases. These patients have either exhausted available treatments or have no approved options. This presentation will review the processes and procedures to consider in the implementation of an Early Access Program and explore the opportunities and challenges posed therein.

Patient Engagement in Drug Development: An Opportunity for Medical Affairs

February 6, 2019

Understand the numerous ways in which partnership with patients can impact the development and commercialization of medicines; the current “patient centric” landscape in pharmaceutical drug development; recent findings related to the value of patient-centric trial design, and innovative approaches to engaging with patients across the study continuum.

Field Based Medical LCM in the Device and Pharma World

November 28, 2018

MSLs are becoming more important and playing key roles across the lifecycle in partnership with many others who play important roles. We will describe the landscape, drivers, and opportunities for engaging with customers across the lifecycle and how we socialize learnings across the organization.

Connect with Us

Follow Us